At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 701 enrolled
Drug / intervention
Erenumabbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study
In Brief
A Phase 4 clinical trial evaluating Erenumab for Migraine and 2 related conditions. Completed, enrolled 701 participants across 75 sites.
Detailed Summary
This is a 128-week open-label study to assess the long-term safety and tolerabilty of the monoclonal antibody erenumab in migraine patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMigraine, Migraine Disorders, Migraine Headache
CountriesGermany
Collaborators--
Timeline
Phase 4CompletedFinished
2020202120222023202420252026
First PostedSep 2019
Enrollment StartSep 2019
Primary CompletionFeb 2023
Study CompletionMar 2023
TodayJul 2026
First PostedSep 10, 2019
Enrollment StartSep 30, 2019
Primary CompletionFeb 23, 2023
Study CompletionMar 13, 2023
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 6.8 years ago
Interventions
Erenumabbiological
Erenumab was supplied as a pre-filled pen (auto-injector) for subcutaneous injection.